Artiva Biotherapeutics (NASDAQ:ARTV) Insider Subhashis Banerjee Sells 7,037 Shares

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) insider Subhashis Banerjee sold 7,037 shares of the stock in a transaction that occurred on Tuesday, May 19th. The shares were sold at an average price of $9.01, for a total transaction of $63,403.37. Following the transaction, the insider owned 144,963 shares in the company, valued at $1,306,116.63. The trade was a 4.63% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Artiva Biotherapeutics Price Performance

Shares of NASDAQ ARTV opened at $8.55 on Wednesday. Artiva Biotherapeutics, Inc. has a one year low of $1.47 and a one year high of $14.53. The firm’s 50 day simple moving average is $8.32 and its two-hundred day simple moving average is $5.65. The stock has a market capitalization of $211.36 million, a P/E ratio of -2.42 and a beta of 2.86.

Artiva Biotherapeutics (NASDAQ:ARTV) last issued its quarterly earnings results on Friday, May 8th. The company reported ($0.95) EPS for the quarter, missing analysts’ consensus estimates of ($0.88) by ($0.07). As a group, equities analysts expect that Artiva Biotherapeutics, Inc. will post -2.45 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts have commented on the stock. Wedbush increased their price target on shares of Artiva Biotherapeutics from $23.00 to $40.00 and gave the company an “outperform” rating in a research report on Monday, May 11th. Needham & Company LLC increased their price target on shares of Artiva Biotherapeutics from $18.00 to $41.00 and gave the company a “buy” rating in a research report on Tuesday, May 12th. Cantor Fitzgerald increased their price target on shares of Artiva Biotherapeutics from $10.00 to $40.00 and gave the company an “overweight” rating in a research report on Monday, May 11th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Artiva Biotherapeutics in a research report on Friday, April 24th. Finally, HC Wainwright increased their price target on shares of Artiva Biotherapeutics from $15.00 to $35.00 and gave the company a “buy” rating in a research report on Friday, May 8th. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $39.00.

Institutional Trading of Artiva Biotherapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Dimensional Fund Advisors LP purchased a new stake in Artiva Biotherapeutics in the first quarter worth $131,000. Sanctuary Advisors LLC purchased a new stake in Artiva Biotherapeutics in the first quarter worth $139,000. Simplify Asset Management Inc. purchased a new position in Artiva Biotherapeutics during the first quarter valued at $150,000. OMERS ADMINISTRATION Corp purchased a new position in Artiva Biotherapeutics during the fourth quarter valued at $91,000. Finally, Marshall Wace LLP purchased a new position in Artiva Biotherapeutics during the fourth quarter valued at $341,000.

Artiva Biotherapeutics Company Profile

Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of allogeneic “off-the-shelf” cell therapies for cancer. The company’s proprietary platform leverages natural killer (NK) cells engineered to express chimeric antigen receptors (CARs) or other targeting modalities, with the goal of delivering potent anti-tumor activity while minimizing the safety and supply limitations associated with patient-derived (autologous) approaches.

Artiva’s pipeline includes multiple lead product candidates designed to address both hematologic malignancies and solid tumors.